Related Experiment Video
Updated: Feb 13, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
A Novel TGFβ Trap Blocks Chemotherapeutics-Induced TGFβ1 Signaling and Enhances Their Anticancer Activity in
Haiyan Zhu1,2, Xiang Gu2, Lu Xia2,3
1Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Abstract:
Purpose: We investigated the mechanisms of how TGFβ pathway is activated by chemotherapeutics and whether a novel TGFβ trap called RER can block chemotherapeutics-induced TGFβ pathway activation and enhance their antitumor activity in gynecologic cancer.Patients and Methods: An unbiased bioinformatic analysis of differentially expressed genes in 31 ovarian cases due to chemotherapy was used to identify altered master regulators. Phosphorylated Smad2 was determined in 30 paired cervical cancer using IHC. Furthermore, the effects of chemotherapeutics on TGFβ signaling and function, and the effects of RER on chemotherapy-induced TGFβ signaling were determined in gynecologic cancer cells.Results: Chemotherapy-induced transcriptome alteration in ovarian cancer was significantly associated with TGFβ signaling activation. Chemotherapy was found to activate TGFβ signaling as indicated by phosphorylated Smad2 in paired cervical tumor samples (pre- and post-chemotherapy). Similar to TGFβ1, chemotherapeutics were found to stimulate Smad2/3 phosphorylation, cell migration, and markers related to epithelial-mesenchymal transition (EMT) and cancer stem cells (CSC). These TGFβ-like effects were due to the stimulation of TGFβ1 expression and secretion, and could all be abrogated by TGFβ inhibitors including a novel TGFβ trap protein called RER both in vitro and in vivo Importantly, combination treatment with RER and cisplatin showed a higher tumor inhibitory activity than either agent alone in a xenograft model of ovarian cancer.Conclusions: Chemotherapeutics can stimulate TGFβ1 production and consequently enhance TGFβ signaling, EMT, and CSC features resulting in reduced chemo-sensitivity. Combination therapy with a TGFβ inhibitor should alleviate this unintended side effect of chemotherapeutics and enhance their therapeutic efficacy. Clin Cancer Res; 24(12); 2780-93. ©2018 AACR.
Insights
Chemotherapy activates the TGFβ pathway, promoting cancer stem cell traits and reducing treatment effectiveness. A novel TGFβ trap, RER, blocks this activation and enhances antitumor activity in gynecologic cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Chemotherapy can inadvertently activate the transforming growth factor beta (TGFβ) pathway.
- This activation is linked to the development of epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) characteristics.
- These changes can lead to reduced sensitivity to chemotherapy and poorer treatment outcomes in gynecologic cancers.
Purpose of the Study:
- To elucidate the mechanisms by which chemotherapeutics activate the TGFβ pathway.
- To evaluate the efficacy of a novel TGFβ trap, RER, in blocking chemotherapy-induced TGFβ activation.
- To assess the potential of RER in combination therapy to enhance antitumor activity in gynecologic cancers.
Main Methods:
- Bioinformatic analysis of gene expression in chemotherapy-treated ovarian cancer.
- Immunohistochemical detection of phosphorylated Smad2 in cervical cancer tissues.
- In vitro and in vivo studies using gynecologic cancer cells and xenograft models to assess TGFβ signaling, EMT, CSC markers, and tumor growth inhibition.
Main Results:
- Chemotherapy-induced transcriptome alterations in ovarian cancer were significantly associated with TGFβ pathway activation.
- Chemotherapy treatment increased phosphorylated Smad2 levels in cervical cancer, indicating TGFβ pathway activation.
- Chemotherapeutics stimulated TGFβ1 production, leading to increased Smad2/3 phosphorylation, cell migration, EMT, and CSC markers, which were abrogated by RER.
- Combination therapy with RER and cisplatin demonstrated superior tumor inhibitory activity compared to monotherapy in an ovarian cancer xenograft model.
Conclusions:
- Chemotherapeutics stimulate TGFβ1 production, enhancing TGFβ signaling, EMT, and CSC features, which contributes to chemoresistance.
- A novel TGFβ trap, RER, effectively inhibits chemotherapy-induced TGFβ signaling and its downstream effects.
- Combination therapy involving RER and chemotherapy holds promise for overcoming chemoresistance and improving therapeutic efficacy in gynecologic cancers.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Social Traps
Mechanisms of Retrovirus-induced Cancers
What is Cell Signaling?
Bacterial Signaling
Endocrine Signaling

